BRANFORD, Conn. / Aug 19, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place at the Lotte New York Palace Hotel, September 8-10, 2025.
Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, September 9, 2025 and Jeff Hawkins will participate in a fireside chat on the same day at 10:00 AM Eastern Time.
A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$2.27 |
Daily Change: | -0.27 -10.63 |
Daily Volume: | 21,579,841 |
Market Cap: | US$414.410M |
September 23, 2025 September 08, 2025 August 05, 2025 June 17, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load